1. Generics Bulletin
  2. >>Products
  3. >>Generics

Podcast: The Global Generics & Biosimilars Awards 2024

All The Details Of Our Latest Ceremony, This Year Taking Place On 9 October In Milan

 
• By Dave Wallace

In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.

Generic Bulletin Podcast
The GGB Awards 2024 will take place on 9 October in Milan

The Global Generics & Biosimilars Awards is now in its eleventh year. In this podcast, Generics Bulletin editors Dave Wallace and Dean Rudge talk about how you can enter and attend the awards – both of which remain free of charge – as well as offering tips for entries and discussing the reasons why off-patent industry players might want to be involved in the event. 

Citeline · 2024 Global Generics & Biosimilars Awards

Open Media

Entries for the Global Generics & Biosimilars Awards 2024 are open until Monday 22 July and can cover any activities undertaken between 1 September 2023 and 31 July 2024. Our prizegiving ceremony will then take place in-person at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week.

Backed by headline sponsor IQVIA, category sponsors include Cerba Research for Company of the Year – Americas, as well as Pharmacloud for our Leader of the Year category.

The awards are also supported by International Health Partners in our corporate social responsibility initiative of the year category. Our 2024 supporters also include the International Generic and Biosimilars Medicines Association.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail Casey.Burwell@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail Jo.Kirkpatrick@citeline.com

More from Generics

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Combating Bioequivalence Data Fraud: Indian CROs Face Mandatory Registration

 
• By Urtė Fultinavičiūtė

As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.

Hypera Lines Up Brazilian Semaglutide Launch Next Year

 
• By Dave Wallace

Speaking as Hypera delivered its full year-results, CEO Breno Oliveira has set out plans for the Brazilian firm to launch an Ozempic rival in its domestic market next year. Meanwhile, the company is dealing with increasingly aggressive local generic competition.

BGMA Hits Back At ABPI Complaints Over UK Pricing Scheme

 
• By Dave Wallace

Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”

More from Products

Alvotech And Advanz Make First Omalizumab Filing

 
• By Dave Wallace

Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025

 
• By Dean Rudge

With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.